THERAPY DOSSIER · th-01248e762be8

Recombinant human GLP-1 (7-36)

Hormone · Recombinant human GLP-1(7-36) is the native glucagon-like peptide-1 (GLP-1 receptor agonist); no confident single-molecule ChEMBL name match returned (marketed agents are analogs e.g. liraglutide/semaglutide)

Non-drug Suggest a correction

Evidence & regulatory context

Mechanism: Recombinant human GLP-1(7-36) is the native glucagon-like peptide-1 (GLP-1 receptor agonist); no confident single-molecule ChEMBL name match returned (marketed agents are analogs e.g. liraglutide/semaglutide)
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25601009 ↗2015Reported benefit

Protective effect of rhGLP-1 (7-36) on brain ischemia/reperfusion damage in diabetic rats.

RatIschaemia-reperfusionCerebral (MCAO/stroke)Sprague-DawleyMaleIntraperitoneal20, 40 and 80 micrograms/kgGiven before reperfusion

Model: Middle cerebral artery occlusion with reperfusion in type 2 diabetic rats (high-fat diet plus low-dose streptozotocin)

Treated groups showed lower neurological deficit scores, smaller percentage infarct volume, lower malondialdehyde, iNOS and blood glucose, and higher superoxide dismutase, glutathione peroxidase and eNOS, with more surviving neurons and increased vascular proliferation.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.

Loading the evidence…